Article Text

Download PDFPDF

Progressive polyradiculoneuropathy in diabetes: correlation of variables and clinical outcome after immunotherapy
  1. Safwan S Jaradeh,
  2. Thomas E Prieto,
  3. Lorri J Lobeck
  1. Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA
  1. Dr Safwan S Jaradeh, Department of Neurology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. Telephone 001 414 454 5200; fax 001 414 259 0469. Received 12 October 1998 and in revised form 26 April 1999 Accepted 6 May 1999


OBJECTIVE To quantify the progression of diabetic polyradiculoneuropathy—a condition in which immune factors have been implicated—after immunotherapy.

METHODS The study evaluated 15 consecutive patients with this condition. All patients were older than 40. Four had type I diabetes and six were women. The duration of pre-existing diabetes varied from 2 to 20 years. The clinical presentation was dominated by painful progressive motor weakness, with or without exacerbation of sensory symptoms. The weakness involved all limbs, but was often asymmetric.

RESULTS Electrophysiological testing showed a predominantly axonal polyneuropathy, with more recent denervating polyradiculopathy. Analysis of CSF showed increased protein in 14 and oligoclonal bands in five. Quantitative autonomic tests showed abnormalities in all patients. Sural nerve biopsy was performed in 14 patients; all showed fibre loss and segmental demyelination, four had occasional onion bulbs, and 10 showed various inflammatory infiltrates. After immunomodulating therapy, there was no further deterioration and clinical improvement occurred in all patients. Sweat responses, cardiovascular reflexes, and sural nerve fibre density correlated best with functional outcome. There was no significant difference between plasmapheresis and intravenous gammaglobulin.

CONCLUSION Immunotherapy may improve this condition, but only certain variables correlate with rapid therapeutic response.

  • diabetes mellitus
  • peripheral nerve diseases
  • polyradiculoneuropathy
  • immunosuppressive treatment

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.